Abstract:According to GLOBOCAN 2018, the global cancer statistic database by the International Agency for Research on Cancer, breast cancer is the most commonly diagnosed cancer in women.[1] In 2018, more than 2 million new breast cancer cases were reported, with an age standardized rate (ASR) of 46.3 per 100,000, and over 600,000 deaths from breast cancer were estimated, with an ASR of 13.0 per 100,000, worldwide. The number of breast cancer cases continues to increase. In China, more than 270,000 new cases were diagnosed in 2015, with 70,000 reported deaths.[2] In 2018, the number of new cases in the country increased to 367,900.[1] Thus, we urgently need more clinical researches and expert consensus on optimal therapies for breast cancer. On the basis of clinical evidence, recommendations for early-stage breast cancer surgery have been widely accepted since the 19th century. In 1894, Halsted successfully performed radical mastectomy, involving resection of pectoralis major and minor muscles as well as axillary and subclavian lymphadenectomy, in breast cancer patients, which, for the first time, resulted in local R0 resection of tumors and a 5-year survival rate >40%. Since then, achieving R0 resection has become the aim of breast cancer surgery. However, the necessity for radical mastectomy was challenged with the emergence of the concepts of systemic disease and systemic therapy. The disadvantages of Halsted radical mastectomy in terms of patients’ quality of life gradually became evident, and the procedure was abandoned in the 20th century. Instead, breast-conserving surgery (BCS) and sentinel lymph node biopsy (SLNB), supported by high-level evidence focusing on both survival and quality of life, became the preferred choice for the treatment of early-stage breast cancer patients. Nonetheless, the basic principle that R0 resection of the primary tumor and regional lymph nodes must be achieved for successful surgery of early-stage breast cancer has not changed. In 1971, the United States of America, Canada, and Australia jointly launched the National Surgical Adjuvant Breast and Bowel Project (NSABP), aiming to standardize breast and bowel cancer treatment by conducting prospective, multi-center clinical studies. The NSABP B-04, B-06, and B-32 trials provided high-quality evidence on BCS and SLNB, which laid the foundation for improving surgical techniques for breast cancer. In 2020, the National Comprehensive Cancer Network (NCCN) clarifies indications and contraindications to BCS, SLNB, and breast reconstruction surgery.[3] However, the optimal surgical margins for BCS, the treatment for limited sentinel lymph node (SLN) metastasis, and the usefulness of SLNB for node-positive patients after neoadjuvant systemic chemotherapy (NST) remain controversial.[4] Molecular subtypes have been widely used in developing individualized treatments for breast cancer since the beginning of the 21st century. In addition to reducing the tumor burden by surgery, the development of cytotoxic, endocrine, targeted, and immune drugs has contributed to individualized treatment on the basis of molecular subtypes. Moreover, improved radiotherapy techniques have led surgeons to re-plan breast surgery to maximize benefits and minimize harm in patients. The safety of omitting axillary lymph node dissection (ALND) in women with positive SLNs, the definition of clear margins of BCS after NST, and the safety of SLNB in patients with positive nodes after NST are still under debate.[5] Currently, Chinese surgeons are highly concerned about standardizing surgical procedures for breast cancer, including core needle biopsy (CNB), BCS, breast reconstruction, and vacuum-assisted breast biopsy (VABB). As many surgeons in China lack radionuclide certification and patients wish to avoid a second operation, the preferred option is to locate SLNs with the single lymphatic technique and assess margins through frozen pathological diagnosis. Therefore, Chinese doctors are encouraged to improve clinical standardization and conduct multi-center studies on the basis of existing global research findings and domestic conditions. The Chinese Society of Breast Surgeons (CSBrS), which includes breast surgeons from 41 large-scale hospitals, was established in 2017 to standardize breast cancer treatment and build a platform for multi-center study. By May 2020, ten guidelines on hot topics on breast cancer had been issued. As diagnosis is the basis of personalized treatment, the 2013 St. Gallen Consensus provided evidence-based treatment recommendations for breast cancer, among which the concept of molecular subtype was included, marking the beginning of a new era in personalized treatment for breast cancer, which could significantly improve prognosis.[6] The NCCN Clinical Practice Guideline highly recommends CNB for suspicious lesions, and other studies have also reported that pre-operative CNB could improve the quality of surgery.[7] However, because of insufficient understanding of the clinical value of CNB, most primary hospitals and even some large general hospitals still insist on open biopsy. Mastectomy is performed on the basis of the results of intra-operative frozen pathological examination, which seriously affects the progress in personalized treatment of early-stage breast cancer in China. In 2019, CSBrS published Consensus statements and operation guidelines on breast lesions and lymph nodes biopsy guided by ultrasound,[8] aiming to raise public awareness on the CNB technique. For patients with benign lesions diagnosed using CNB, the goal is to minimize invasive surgery. VABB has the unique advantages of accuracy, convenience, and minimal incision when handling breast lesions. To promote this technique and avoid complications, CSBrS published Consensus statements and operation guidelines on ultrasound-guided vacuum-assisted breast biopsy[9] in 2017. For patients whose lesions test positive for cancer on CNB, the main aim is to maximize quality of life and minimize harm while providing effective treatment. The NSABP-B32 trial[10] found that patients with clinical lymph node-negative breast cancer can safely avoid ALND and lymphedema if SLNs are negative. Because of the unavailability of radionuclide and isosulfan blue, most Chinese doctors use methylene blue or carbon nanoparticles to locate SLNs. To generalize the SLNB technique in early-stage breast cancer, CSBrS published Consensus statements and operation guidelines on sentinel lymph nodes biopsy in early breast cancer[11] in 2018. Although it is publicly known that for selected patients with early breast cancer BCS is safe and has a good aesthetic result, the average percentage of BCS is no more than 30% in China. To clarify the indications, contraindications, and surgical technique of BCS, CSBrS published A consensus statement on the breast-conserving surgery of early-stage breast cancer[12] in 2019. According to the NCCN guidelines, all patients with breast cancer, especially those who need mastectomy, should receive consultation on breast reconstruction before surgery. However, oncologic safety is always the premise of any reconstruction, so reconstruction should have no impact on the timing of oncological surgery and surveillance. Reconstruction surgery with any residual tumor is a failure, regardless of post-operative appearance. Multidisciplinary teamwork is required for successful reconstruction.[13] As the oncology field develops rapidly, the breast surgery department has become an independent department in both cancer and general hospitals in China. It is now possible to conduct domestic multi-center clinical studies. By 2019, ten multi-center studies on trending topics on breast cancer had been initiated, and more studies have been planned in 2020. CSBrS will make every effort to promote the development and standardization of clinical treatment of breast cancer in China. Conflicts of interest None.

Abstract:With the maturation and advances of image-guided puncture biopsy technology, the proportion of open breast biopsy has gradually decreased. Ultrasound-guided biopsy is convenient in practice and supports real-time visualization. In order to standardize the practice of ultrasound-guided breast and regional lymph node biopsy, and provide a reference for Chinese breast surgeons, based on the version of Consensus statements and operation guidelines on breast lesions and lymph nodes biopsy guided by ultrasound (2019),[1] the Chinese Society of Breast Surgery (CSBrS) has re-evaluated the quality of the evidence of relevant clinical studies referring to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) handbook and considered domestic medical condition to develop the Clinical Practice Guidelines for Ultrasound-guided Breast Lesions and Lymph Nodes Biopsy: CSBrS Practice Guidelines 2021. Level of evidence and recommendation strength Level of evidence standard[2] Recommendation strength standard[2] Recommendation Strength Review Committee A total of 79 members of the voting committee of this guideline, including 68 breast surgeons (86.1%), two oncologists (2.5%), four radiologists (5.1%), two pathologist (2.5%), one radiation therapist (1.3%), and two epidemiologists (2.5%). Target Audience Clinicians specializing in breast diseases in China. Recommendations Recommendation 1: Indications - Site Indications Level of evidence Recommendation strength 1.1 Breast Lesion Breast Imaging Reporting and Data System (BI-RADS) category ≥ 4[3–5] I A 1.2 BI-RADS category 3 with a family history of breast cancer or other high-risk factors[1] II A 1.3 Possible for neoadjuvant therapy[3,4] I A 1.4 Benign lesion for further pathological classification[4] I A 1.5 Regional Lymph Node Suggested by imaging with abnormal histomorphology and (or) structure, and suspected of being metastatic[6] I A Recommendation 2: Methods for breast lesion biopsy - Methods for breast lesion biopsy Level of evidence Recommendation strength 2.1 Fine-needle aspiration biopsy (FNAB)[5] III B 2.2 Core needle biopsy (CNB)[3,7,8] I A 2.3 Vacuum-assisted breast biopsy (VABB)[4] I A Recommendation 3: Methods for regional lymph node biopsy - Methods for regional lymph node biopsy Level of evidence Recommendation strength 3.1 FNAB[9] I A 3.2 CNB[6] I A Recommendation 4: Clinical issues on breast lesion biopsy - Clinical issues on breast lesion biopsy Level of evidence Recommendation strength 4.1 Needle size for breast lesion CNB 4.1.1 14G[10–12] II A 4.1.2 16G[10–12] II A 4.1.3 18G[10,12] III B 4.2 ≥4 specimens for breast lesion CNB to improve the diagnostic rate (with 14G needle)[13,14] II A 4.3 CNB or VABB specimens may have pathological underestimation of the following breast lesions 4.3.1 High-risk lesions Papilloma[15,16] I A 4.3.2 Atypical ductal hyperplasia (ADH)[4,16] I A 4.3.3 Phyllodes tumor[16,17] II A 4.3.4 Radial sclerosing lesion[16] II A 4.3.5 Carcinoma in situ[4,16] I A Discussion The contraindications of ultrasound-guided breast lesion or regional lymph node biopsy can refer to the general principles for preoperative evaluation, including severe systemic diseases, mental disorders, inability to cooperate, and severe bleeding or coagulation disorder. The following conditions should be considered as relative contraindications and be treated carefully regarding the status of individuals: prosthesis-adjacent lesions and lesions with macro-calcification. Yu et al[5] reported the satisfying sensitivity and specificity of fine-needle aspiration biopsy (FNAB) with adequate sample obtained for diagnosis, in a meta-analysis of 46 studies involving 7207 patients; however, in 11 studies which reported unsatisfactory samples, 27.5% of patients were subsequently upgraded to various grade cancers. The diagnosis and treatment of breast cancer have entered the era of molecular typing, while FNAB cannot provide histopathology. In addition, cellular immunohistochemistry has not been popularized and standardized domestically yet. Therefore, the expert panel does not recommend FNAB as a first-line method for breast lesion biopsy. The core needle biopsy (CNB) can collect specimens for histopathological diagnosis. The diagnostic sensitivity of CNB is 96%,[3] and the findings on the status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression in CNB specimens show good consistency with the immunohistochemical findings of surgical specimens.[7,8] There is no direct clinical evidence showing decreased overall survival of patients undergoing a CNB for breast cancer,[18] but we recommend resecting the needle track during the breast surgery to minimize the probability of cancer recurrence and metastasis. However, CNB specimens may show false-negative findings and histopathological underestimation for small lesions, heterogeneous tumors, or special pathological types.[19] Youk et al[16] systematically reviewed 2,420 lesions from 2,198 women who undergone sonographically guided 14-gauge CNB, and the results suggested that the underestimate rate was 29% for ductal carcinoma in situ (DCIS) and the overall underestimation rate of high-risk lesions was 27%, in which the underestimation rate of atypical ductal hyperplasia (ADH) and other high-risk lesions was 52% and 17% respectively. It is thereby seen that CNB has a relatively high pathological underestimation rate for the diagnosis of special pathological types. More details on vacuum-assisted breast biopsy (VABB) usage and diagnostic underestimation can be found in Clinical Practice Guidelines for Ultrasound-guided Vacuum-assisted Breast Biopsy: CSBrS Practice Guidelines 2021.[20] Clinicians should consider performing a subsequent open surgical resection to make a definitive diagnosis for the abovementioned conditions. Open surgical biopsy should also be conducted if there is an obvious inconsistency between the puncture biopsy results and the imaging examination. Ultrasound-guided FNAB was most frequently used in the clinic for regional lymph nodes biopsy; however, it only supports cytological materials collection. It cannot accurately identify abnormal morphology or the structure of lymph node tissues, or execute the immunohistochemical evaluation of the tumor, which may result in the pathological underestimation. CNB can well make up for the shortcomings of FNAB. Balasubramanian et al[6] found that the sensitivity of the diagnosis of a lymph node metastasis was 88% for ultrasound-guided CNB and 74% for FNAB in general. The specificity of CNB and FNAB were similar, approaching 100%. Since both the axillary and clavicular regional lymph nodes are usually adjacent to blood vessels and nerves, an ultrasound-guided biopsy should be carefully performed with the use of a suitable needle to minimize secondary injuries. Conflicts of interest The expert committee for these guidelines declares no conflict of interest. These guidelines are a reference for breast disease specialists in clinical practice. However, the guidelines are not to be used as the basis for medical evaluation, and do not play an arbitrating role in the handling of any medical disputes. The guidelines are not a reference for patients or non-breast specialists. The Chinese Society of Breast Surgery assumes no responsibility for results involving the inappropriate application of these guidelines, and reserves the right to interpret and revise the guidelines. List of Compiling Committee Members (in alphabetical order by surname) Zhong-Wei Cao, Bo Chen, De-Dian Chen, Lu-Yan Chen, Yuan-Jia Cheng, Xue-Ning Duan, Zhi-Min Fan, Pei-Fen Fu, Bao-Liang Guo, Jian Haung, Jun Jiang, Hong-Chuan Jiang, Feng Jin, Hua Kang, Rui Ling, Jin-Ping Liu, Ke Liu, Qian Liu, Yin-Hua Liu, Yun-Jiang Liu, Zhen-Zhen Liu, Yong-Hui Luo, Jin-Fei Ma, Rong Ma, Da-Hua Mao, Jiang-Hua Ou, Xiang Qu, Guo-Sheng Ren, Ai-Lin Song, Er-Wei Song, Li-Li Tang, Xing-song Tian, Chuan Wang, Fei Wang, Jian-Dong Wang, Shu Wang, Shui Wang, Xiang Wang, Qian Wu, Jiong Wu, Ke-Jin Wu, Shuang-Ling Wu, Fei Xie, Ling Xin, Zhi-Gang Yu, Jian-Guo Zhang, Jin Zhang, Jing-Hua Zhang, Yi Zhao, Zuo-Wei Zhao, Wei Zhu, Ang Zheng, Qiang Zou.

To establish high-quality clinical practice guidelines and promote the standardization of diagnosis and treatment of breast disease in China

Introduction to the Key Contents of the Chinese Society of Breast Surgery Practice Guideline 2021

Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022

Clinical practice guidelines for diagnosis and treatment of invasive breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Laying equal stress on research and clinical guidelines to promote the development of breast surgery in China

Clinical practice guidelines for neoadjuvant therapy in patients with early-stage breast cancer: Chinese Society of Breast Surgery practice guidelines 2022

Clinical practice guidelines for ductal carcinoma in situ: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Clinical practice guidelines for breast cancer implantable intravenous infusion ports: Chinese Society of Breast Surgery practice guidelines 2021

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024

The Quality of Clinical Practice Guidelines in China: a Systematic Assessment.

Chinese Breast Cancer Surgery: Clinical Practice and Research

Clinical Practice Guidelines for Ultrasound-Guided Breast Lesions and Lymph Nodes Biopsy: Chinese Society of Breast Surgery (csbrs) Practice Guidelines 2021

Interpretation of“guideline and standard for the diagnosis and treatment of breast cancer by Chinese ;Anti-Cancer Association (2015 edition)”:surgical section

Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China

Scientificity, transparency, and applicability of Chinese guidelines and consensus on burn/plastic surgery published in 2022

Analysis of the Status and Trends of Chinese Clinical Practice Guideline Development Between 2010 and 2020: A Systematic Review

Chinese national clinical practice guidelines on prevention, diagnosis and treatment of early colorectal cancer

Clinical Practice Guidelines for Visualized Percutaneous Breast Tissue Clips: Chinese Society of Breast Surgery (csbrs) Practice Guideline 2021

Guideline for [clinical Guidelines Constitution/Amendment] in China.

Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022